Battling For Health → Addiction • Alzheimer • Arthritis • Cancer • Depression • Diabetes • Healthcare • Heart • M.S. • Obesity • Schizo • Stress • Vision
Archive for the News category
Roche is happy to announce that its rheumatoid arthritis drug Actemra (tocilizumab) has won the recommending approval of the US FDA’s Arthritis Advisory Committee.
The committee’s vote was made after Roche presented results from five Phase III clinical trials. The clinical development program evaluated the effects of Actemra on signs and symptoms of RA, physical function, progression of structural damage, and health-related quality of life.
What: Workshop On Rheumatoid Arthritis
When: 1:30 p.m. Wednesday, July 30, 2008
Where: Holiday Inn Express (North Platte, Nebraska)
Sponsored by Great Plains Regional Medical Center (GPRMC) and North Platte Orthopedic and Sports Medicine, this workshop is free and open to the public.
If anybody reading this is near the area, you may want to drop by and listen to Dr. E. Scott Carroll present the seminar: More →
The UK’s National Institute for Health and Clinical Excellence (Nice) decision on arthritis drug will prevent tens of thousands of arthritis sufferers to switch to powerful drugs.
In a separate post I already mentioned UK Nice’s ruling that do not allow switching of arthritis drug to more powerful ones, once the patient do not respond in one in the premise that it isn’t cost effective. Now the final draft on that ruling (before definitive guidance is issued) has been issued by Nice already.
Charity groups and arthritis patients alike are going berserk of course, simply because this ruling will prevent access of arthritis patients to hopefully better drugs to manage their arthritis.
As reported by Wyeth - maker of the rheumatoid arthritis drug Enbrel - the combination of the drug Enbrel and methotrexate help improve to remission of rheumatoid arthritis.
Wyeth Pharmaceuticals (a division of Wyeth) and Amgen today announced the publication of data from the COMET (COmbination of Methotrexate and ETanercept in Active Early Rheumatoid Arthritis) trial demonstrating that half of patients treated with the combination of ENBREL and methotrexate achieved Disease Activity Score (DAS) clinical remission and nearly all had no progression of joint damage.
Orencia (abatacept) - a product of Bristol-Myers Squibb - is in the news today.
ORENCIA® (abatacept) is a prescription medicine that can reduce signs and symptoms in adults with moderate to severe rheumatoid arthritis (RA) — including those who have not been helped enough by other medicines for RA. ORENCIA can further damage the bones and joints which can also reduce signs and symptoms in children and adolescents 6 years of age and older with moderate to severe polyarticular juvenile idiopathic arthritis (JIA).
Many times here I have mentioned that arthritis in children isn’t uncommon anymore these days. Statistics show that the rate children being diagnosed with juvenile rheumatoid arthritis is increasing.
In the U.S. alone:
A recent Centers for Disease Control study estimates that nearly 300,000 children in this country suffer from some form of arthritis.
I have read about the application of apitherapy against arthritis and might have mentioned it here in passing. Apitherapy is the medical use of honey bee products such as honey, pollen, propolis, royal jelly, and bee venom.
Though in arthritis, apitherapy refers more to bee venom therapy than the consumption of other bee products.
In lieu of the recent EULAR 2008 (the Annual European Congress of Rheumatology in Paris, France), updates are abound regarding the developments of arthritis drugs, either of those already existing in the market but most especially of those that are still under clinical trials.
1. CEL-SCI Announces Discovery of Novel Compound for the Treatment of Rheumatoid Arthritis More →
Okay, before you all get too excited with the title, let us all remember the word moderation when pertaining to alcohol intake. 
Now…studies are claiming that it may be possible that drinking five glasses of wine per week can reduce the risk of the onset of rheumatoid arthritis by 50 percent.
A product of Eli Lilly, Cymbalta® - is a balanced and potent reuptake inhibitor of serotonin and norepinephrine, believed to potentiate the activity of these chemicals in the central nervous system (brain and spinal cord).
While the mechanism of action of Cymbalta is not fully known, scientists believe its effects on depression and anxiety symptoms, as well as its effect on pain perception, may be due to increasing the activity of serotonin and norepinephrine in the central nervous system.
I would like the patients to understand their condition better in order to help them discern what is best for their life with arthritis in conjunction to what their doctors are telling them! .. More ..
Search the HART-Empire Network of sites, including this one, with the search form below.
Battling Arthritis is Copyright © HART-Empire Network • Powered by WordPress
Original network template design by Thord Daniel Hedengren • HART'icized by HART (1-800-HART)
